Clinical role of β-lactam/β-lactamase inhibitor combinations

Drugs

Volumn 63, Issue 14, 2003, Pages 1511-1524

  Lee, Nelson ^a   Yuen, Kwok Yung ^a   Kumana, Cyrus R ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; LEVOFLOXACIN; OXACILLIN; PENICILLANIC ACID; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; SULFONE DERIVATIVE; SULPERAZON; SULTAMICILLIN; TAZOBACTAM; TIMENTIN; UNINDEXED DRUG;

ABDOMINAL INFECTION; ACID FAST BACTERIUM; ACINETOBACTER; ANAEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; CHOLESTATIC HEPATITIS; CLOSTRIDIUM DIFFICILE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TOLERABILITY; ENTEROCOCCUS; ENZYME INACTIVATION; ENZYME INHIBITION; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; INFECTION; LIVER TOXICITY; NEUTROPENIA; OUTPATIENT; RASH; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STENOTROPHOMONAS MALTOPHILIA;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; COMMUNICABLE DISEASES; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS;

ACINETOBACTER; BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE; ENTEROCOCCUS; NEGIBACTERIA; POSIBACTERIA; STENOTROPHOMONAS MALTOPHILIA;

EID: 0038443270     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363140-00006     Document Type: Review

References (87)

1. Virk A, Steckelberg JM. Clinical aspects of antimicrobial resistance. Mayo Clin Proc 2000; 75: 200-14
2. Bush K. New β-lactamases in gram-negative bacteria: diversity and impact on selection of antimicrobial therapy. Clin Infect Dis 2001; 32: 1085-9
3. Prabhakaran K, Harris EB, Randhawa B. Bactericidal action of ampicillin/sulbactam against intracellular mycobacteria. Int J Antimicrob Agents 1999; 13 (2): 133-5
4. Wright AJ. The penicillins. Mayo Clin Proc 1999; 74: 290-307
5. Amyes SGB. Genes and spectrum. Clin Infect Dis 1998; 27 Suppl. 1: S21-8
6. Aldridge KE, Ashcraft D, Cambre K, et al. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother 2001; 45: 1238-43
7. Williams JD. β-lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin Infect Dis 1997; 24: 494-7
8. SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 Suppl. 2: S81-113, S147-155
9. Backo M, Gaenger E, Burkart A, et al. Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam. Antimicrob Agents Chemother 1999; 43: 2565-8
10. Schito GC, Georgopoulos A, Prieto J. Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries. J Antimicrob Chemother 2002; 50: 7-11
11. Balko T, Karlowsky JA, Palatnick LP, et al. Characterization of inoculum effect with haemophilus influenzae and beta-lactams. Diagn Microbiol Infect Dis 1999; 33: 47-58
12. Sirot D. Extended-spectrum plasmid-mediated β-lactamases. J Antimicrob Chemother 1995; 36 Suppl. A: 19-34
13. Nagano R, Adachi Y, Imamura H, et al. Carbapenem derivatives as potential inhibitors of various β-lactamases, including class B metallo-β-lactamases. Antimicrob Agents Chemother 1999; 43: 2497-503
14. Lister PD, Gardner VM, Sanders CC. Clavulanate induces expression of Pseudomonas aeruginosa AmpC cephalosporinase at physiologically relevant concentrations and antagonizes the antibacterial activity of ticarcillin. Antimicrob Agents Chemother 1999 Apr; 43 (4): 882-9
15. De la Pena A, Derendorf H. Pharmacokinetic properties of β-lactamase inhibitors. Int J Clin Pharmacol Ther 1999; 37: 63-75
16. William AC. Does the dose matter? Clin Infect Dis 2001; 33: S233-7
17. Munoz P, Garcia-Garrote F, Bouza E. Broad-spectrum β-lactam antibiotics with β-lactamase inhibitors. Int J Antimicrob Agents 1996; 7: S9-S14
18. Saito A, Shimada J, Ohmori M, et al. Phase I study of sulbactam. Chemotherapy 1984; 32 Suppl. 4: 192-201
19. Kumada T. Phase I study of sulbactam/cefoperazone (6-times administration trial). Chemotherapy 1984; 32 Suppl. 4: 214-21
20. Parfitt K, Sweetman SC, Blake PS, et al. Martindale: the complete drug reference. 32th ed. London: Pharmaceutical Press, 1999
21. Thomas C, Steven CB, Sabine R, et al. Comparison of ampicillin-sulbactam and ticarcillin-clavulanic acid in patients with chronic renal failure: effects of differential pharmacokinetics on serum bactericidal activity. Pharmacotherapy 1994; 14: 147-52
22. Nakagawa K, Momono S, Sasaki YU, et al. Preoperative administration of a sulbactam/cefoperazone mixture during cholecystectomy. Surgical Care 1990; 32 (6): 875-9
23. Todd PA, Benfield P. Amoxicillin/clavulanic acid: an update. Drugs 1990; 39: 264-307
24. Pitts NE, Gilbert GS, Knirsch AK, et al. Worldwide clinical experience with sultamicillin. APMIS Suppl 1989; 5: 23-4
25. Seto WH, Chiang TY, Kou M, et al. Hospital antibiotic prescribing successfully modified by immediate concurrent feedback. Br J Clin Pharmacol 1996; 41: 229-34
26. Settle CD, Wilcox MH, Fawley WN, et al. Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin-tazobactam. Aliment Pharmacol Ther 1998; 12: 1217-23
27. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination: report of 15 cases. Gut 1992; 33: 368-71
28. Hedberg M, Lindqvist L, Tuner K, et al. Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1992; 11: 1100-4
29. Eugene BB. Current guidelines for the treatment and prevention of nosocomial infections. Drugs 1999; 58: 51-67
30. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian infectious diseases society and the Canadian thoracic society. Clin Infect Dis 2000; 31: 383-421
31. Brun-Buisson C, Sollet JP, Schweich H. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis 1998; 26: 346-54
32. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998 Nov; 42 (11): 2966-72
33. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intraabdominal infections. Antimicrob Agents Chemother 1992; 36: 2766-72
34. Akyurek N, Bedirli A, Kucuk KC, et al. Randomised comparison of cefoperazone-sulbactam and imipenem-cilastatin in the treatment of intra-abdominal infections [abstract]. Br J Surg 1997; 84: 880
35. Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995; 39: 445-52
36. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002; 50: 79-88
37. Winston DJ, Bartoni K, Bruckerner DA, et al. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 1998; 26: 576-83
38. Finberg RW, Talcott JA. Fever and neutropenia: how to use a new treatment strategy. N Engl J Med 1999; 341: 362-3
39. McKinnon PS, Paladino JA, Grayson ML, et al. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997; 24: 57-63
40. Talan DA, Summanen PH, Finegold SM. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft tissue abscesses in patients with or without histories of injection drug abuse. Clin Infect Dis 2000; 31: 464-71
41. Alan LB, Michael AG, Jack MG, et al. Diagnosis and management of group A streptococcal pharyngitis: a practice guideline. Clin Infect Dis 1997; 25: 574-83
42. Kuriyama T, Karasawa T, Nakagawa K, et al. Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections. Oral Microbiol Immunol 2001; 16: 10-5
43. Mandell GL, Bennett JE, Dolin R. Principle and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000: 689-699, 2641-2642
44. Goldstein FW. Penicillin-resistant Streptococcus pneumoniae: selection by both β-lactam and non-β-lactam antibiotics. J Antimicrob Chemother 1999; 44: 141-4
45. Douglas S, Peter D. Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. Clin Infect Dis 2001; 33: S193-205
46. John GB, Scott FD, Lionel AM, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-82
47. Craig WA. The future: can we learn from the past? Diagn Microbial Infect Dis 1997; 27: 49-53
48. Thorburn CE, Knott SJ, Edwards DI. In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumoncocci and potential to select resistance. Antimicrob Agents Chemother 1998; 42: 1973-9
49. Auckenthaler R. Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. J Antimicrob Chemother 2002; 50: 13-7
50. Gleason PP, Meehan TP, Fine JM, et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72
51. Ho PL, Tse WS, Tsang KWT, et al. Risk factors for acquisition of levofloxacin-resistant streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701-7
52. Quenzer RW, Pettit KG, Arnold RJ, et al. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection. Am J Manag Care 1997; 3: 1027-36
53. Dilip N, Ethan R, Gavin B, et al. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001; 32: 728-41
54. Chanal C, Bonnet R, De Champs C, et al. Prevalence of beta-lactamases among 1072 clinical stains of Proteus mirabilis: a 2 year survey in a French hospital. Antimicrob Agents Chemother 2000; 44: 1930-5
55. Kaye KS, Harris AD, Gold H, et al. Risk factors for recovery of ampicillin-sulbactam resistant Escherichia coli in hospitalised patients. Antimicrob Agents Chemother 2000; 44: 1004-9
56. Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumonia: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32: 1162-71
57. Davey PG, Vacani P, Parker SE, et al. Assessing cost effectiveness of antimicrobial treatment: monotherapy compared with combination therapy. Eur J Surg Suppl 1994; 573: 67-72
58. Claude M, Agnes C, Annick G, et al. Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continous infusion in tissues of patients undergoing colorectal surgery. Antimicrob Agents Chemother 1998; 42: 1093-7
59. Carmen B, Ana S, Maria G, et al. In vitro susceptibility of species of the Bacteroides fragilis group to newer β-lactam agents. J Antimicrob Chemother 1999; 43: 133-6
60. Ninin E, Moreau P. Andre-Richet B, et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001; 33: 41-7
61. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51
62. Davidson RN, Wall RA. Prevention and management of infections in patients without a spleen. Clin Microbiol Infect 2001; 7: 657-60
63. Talan DA, Citron DM, Abrahamian FM, et al. Bacteriological analysis of infected dog and cat bites. N Engl J Med 1999; 340: 85-92
64. Nichols RL, Florman S. Clinical presentations of soft tissue infections and surgical site infections. Clin Infect Dis 2001; 33 Suppl. 2: S84-93
65. Asensio A, Guerrero A, Quereda C, et al. Colonization and infection of methicillin resistant Staphylococcus aureus: associated factors and eradication. Infect Control Hosp Epidemiol 1996; 17: 20-8
66. Pefanis A, Thauvin-Eliopoulos C, Eliopoulos GM, et al. Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus. Antimicrob Agents Chemother 1993; 37: 507-11
67. Hiramatsu K, Hanaka H, Ino T, et al. Methicillin- resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Agents Chemother 1997; 40: 135-6
68. Lister PD. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa. Pharmacotherapy 2000; 20: 213S-8S
69. Corbella X, Ariza J, Ardanuy C, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42: 793-802
70. Leelarasamee A. Burkholderia pseudomallei: the unbeatable foe? Southeast Asian J Trop Med Public Health 1998; 29: 410-5
71. Chetchotisakd P, Porramatikul S, Mootsikapun P, et al. Randomized, double-blind, controlled study of Cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin Infect Dis 2001; 33: 29-34
72. Livermore DM, Brown DFJ. Detection of β-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48 Suppl. 1: 59-64
73. Essack SY. Treatment options for extended-spectrum beta-lactamase-producers. FEMS Microbiol Lett 2000; 190: 181-4
74. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3
75. Rice LB, Eckstein EC, Vente JD, et al. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland department of Veterans affairs medical center. Clin Infect Dis 1996; 23: 118-24
76. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. J Antimicrob Agents Chemother 1998; 42: 53-8
77. Drusano GL. Infection in the intensive care unit: β-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clin Infect Dis 1998; 27 Suppl. 1: S111-6
78. Calil R, Marba ST, von Nowakonski A, et al. Reduction in colonization and nosocomial infection by multiresistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. Am J Infect Control 2001; 29: 133-8
79. Higashitani F, Nishida K, Hyodo A, et al. Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants). J Antibiot (Tokyo) 1995; 48: 1027-33
80. Kadima TA, Weiner JH. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam. Antimicrob Agents Chemother 1997; 41: 2177-83
81. Pfaller MA, Jones RN, Marshall SA, et al. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997; 28: 211-9
82. Bradley SJ, Wilson ALT, Allen MC, et al. The control of hyperendemic glycopeptide-resistant Enterococcous spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999; 43: 261-6
83. Quale J, Landman D, Saurina G, et al. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23: 1020-125
84. Sullivan A, Edlund C, Nord CE. Effect of antimicrobial agents on the ecology balance of human microflora. Lancet Infect Dis 2001; I: 101-14
85. Gould IM. A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999; 43: 459-65
86. Chaibi EB, Sirot D, Paul G, et al. Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999; 43: 447-58
87. Leflon-Guibout V, Speldooren V, Heym B, et al. Epidemiology survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla (TEM) genes. J Antimicrob Agents Chemother 2000; 44: 2709-14